As immunotherapeutic approaches combining “anti-CAF” and “anti-PD-L1” have exhibited some promising results [50]; this combined therapy may contribute to a potential strategy for BC patients with high IRGPI scores. This evidence concerns the gene CD274 and breast cancer.